Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

KTRADelisted Stock  USD 6.30  0.14  2.17%   
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. , announced that the two parties have entered into a strategic collaboration regarding limertinib, a third-generation epidermal growth factor receptor EG

Read at finance.yahoo.com
Yahoo News
  

Kintara Therapeutics Fundamental Analysis

We analyze Kintara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Asset

Return On Asset Comparative Analysis

Kintara Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Kintara Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kintara Therapeutics stock to make a market-neutral strategy. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with similar companies.

Peers

Kintara Therapeutics Related Equities

FBRXForte Biosciences   9.70   
0%
100.0%
DMACDiaMedica Therapeutics   8.64   
0%
89.0%
TOVXTheriva Biologics   7.46   
0%
76.0%
MCRBSeres Therapeutics   6.52   
0%
67.0%
MISTMilestone Pharmaceuticals   6.42   
0%
66.0%
VCNXVaccinex   2.44   
0%
25.0%
BOLTBolt Biotherapeutics   1.59   
0%
16.0%
CLRBCellectar Biosciences   0.65   
0%
6.0%
LBPHLongboard Pharmaceuticals   0.03   
0%
1.0%
LUMOLumos Pharma   0.46   
4.0%
0%
SABSSAB Biotherapeutics   1.02   
10.0%
0%
SLRXSalarius Pharmaceuticals   1.38   
14.0%
0%
ONCYOncolytics Biotech   2.11   
21.0%
0%
LSTALisata Therapeutics   2.13   
21.0%
0%
GOVXGeoVax Labs   2.58   
26.0%
0%
SCPHScpharmaceuticals   3.21   
33.0%
0%
DYAIDyadic International   8.56   
88.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Consideration for investing in Kintara Stock

If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas